SCYNEXIS reports Phase 1 data show SCY-770 well tolerated in healthy adults for ADPKD program
SCYX•SCYNEXIS reported completed Phase 1 results for SCY-770, which was well tolerated with a favorable safety profile in healthy adults. The data supported dose selection for a Phase 2 proof-of-concept trial targeted to start in Q4 2026.
1. Phase 1 results
SCYNEXIS reported completed Phase 1 results for SCY-770, an oral AMPK activator in development for ADPKD. The results showed the drug was well tolerated with a favorable safety profile in healthy adults and supported dose selection for a Phase 2 proof-of-concept trial, still targeted to start in Q4 2026; SCY-770 holds FDA orphan drug designation for ADPKD.
